Month: February 2021

Birmingham spinout secures £800k for point-of-care diagnostics platform

Written by Louise Stanley on 24/02/2021. Posted in Early diagnosis and detection.

Birmingham-based Linear Diagnostics Ltd has secured £800,000 from the Midlands Engine Investment Fund (MEIF) and other investors in the company’s second round of funding, which will enable the company to commence the development of the hardware platform for its tests.

The finance will facilitate the ongoing development of the company’s high-speed platform technology for point of care diagnostics. The funding package includes backing from MEIF Equity Finance, managed by venture capital firm Midven, the University of Birmingham and the UKI2S Fund. The UK Future Fund matched the investment from the initial investors.

Linear Diagnostics was founded in 2011 by Professor Tim Dafforn and Dr Matt Hicks as a spinout from BHP founder-member the University of Birmingham’s School of Biosciences. Its diagnostics technology is based on research in linear dichroism, patented by University of Birmingham Enterprise, which uses polarised light to detect the presence of molecules in solutions.

The company has shown strong technical progress since its first investment, achieving clinical levels of accuracy in tests within its lab environment. Initially focusing on sexually transmitted infections (STIs), Linear Diagnostics is developing a rapid test for chlamydia and gonorrhoea. The test will be capable of detecting multiple infections in the same sample in around 15 minutes by labelling each infection indicator with a different coloured dye.

The World Health Organization estimates that worldwide, more than one million STIs are acquired every day. As most STIs show no or mild symptoms, point of care diagnostics will enable healthcare professionals to provide efficient, on-the-spot treatment, which will help reduce onward transmission and lower the risk of antibiotic resistance.

Brendan Farrell, Chairman & CEO of Linear Diagnostics, said: “We are very grateful to our existing investors for their continued support and to the UK Future Fund for providing matched funding. The funds received will enable Linear Diagnostics to develop a prototype single use cartridge and reader for our duplex test for chlamydia and gonorrhoea.”

Roger Wood, Director at Midven, said: “The requirement for rapid and accurate point of care diagnostics has been brought into sharp focus by the COVID-19 pandemic. There are many other disease areas that could equally benefit from this approach and Linear Diagnostics is making excellent progress with the development of its testing platform. This funding round will enable the company to continue its good work at pace.”

Oliver Sexton, Director at UKI2S, said: “Linear Diagnostics’ platform will be able to identify the presence or absence of genetic biomarkers in under 20 minutes. Such rapid gene-based diagnosis is transformative for diseases and disorders that respond to extremely rapid intervention or require diagnosis outside access to centralised laboratory services”

Ken Cooper, Managing Director at the British Business Bank, said: “This latest investment shows how MEIF Equity Finance can be used for further rounds of funding by businesses at different stages of their growth journey. It’s an example of how MEIF and the Government’s Future Fund are helping to support the continued development of innovative businesses across the Midlands, which is also likely to have a significant public health impact.”

Tim Pile, Chair of the Greater Birmingham and Solihull Local Enterprise Partnership, said: “It is hugely exciting to hear that Linear Diagnostics Ltd has secured MEIF funding. Given the challenges presented by Covid-19, it is critical we do what we can to advance our regional offering in diagnostic technology. We welcome this investment which will ensure better outcomes for patients and opportunities for businesses. GBSLEP is committed to helping create opportunities in the health tech sector which we see as a priority growth area in the region.”

The Midlands Engine Investment Fund project is supported financially by the European Union using funding from the European Regional Development Fund (ERDF) as part of the European Structural and Investment Funds Growth Programme 2014-2020 and the European Investment Bank.

Ed Smith - Yve Buckland - Robert Lechler

Three high-profile appointees heighten ambition for Birmingham Health Partners

Written by Louise Stanley on 19/02/2021. Posted in Birmingham Health Partners.

The second city’s University-NHS partnership Birmingham Health Partners (BHP) has made three high-profile appointments to its leadership board – announcing Professor Sir Robert Lechler and Dame Yve Buckland as Non-Executive Directors and former Chairman of NHS Improvement and Deputy Chairman of NHS England, Ed Smith, as independent Chair.

BHP is a strategic alliance which aims to rapidly translate healthcare research findings into new diagnostics, drugs and devices for patients. Its members are: University Hospitals Birmingham, England’s largest acute NHS Trust; Birmingham Women’s and Children’s Hospitals – the first NHS Foundation Trust of its kind; the University of Birmingham; and the West Midlands Academic Health Science Network.

Having recently stepped down from his roles as Senior Vice-President (Health) at King’s College London and Executive Director of King’s Health Partners Academic Health Sciences Centre, Professor Sir Robert Lechler brings a wealth of health research experience to the role of Non-Executive Director of BHP. A strong advocate of university-NHS partnership, Sir Robert was awarded a knighthood for Services to Academic Medicine in 2012 following a research career focused on clinical transplantation tolerance. His work has led to pioneering cell therapies to aid the immune tolerance of kidney and liver transplant recipients.

Commenting on his appointment to the BHP board, Professor Sir Robert commented: “The organisations which make up BHP could not be closer – either in their physical locations or their ethos. The ecosystem has been designated a Life Sciences Opportunity Zone by Government, and will soon begin work on the latest addition – the Birmingham Health Innovation Campus. BHP and its wider regional partners are already working to address pressing health challenges and deliver economic growth, and the refreshed board are ready to mobilise further advancements.”

Also joining BHP as Non-Executive Director is the outgoing chair of Birmingham’s Royal Orthopaedic Hospital NHS Foundation Trust, Dame Yve Buckland. Her appointment to BHP coincides with her new role as Chair of Birmingham and Solihull integrated care system (ICS), which will forge closer links between primary, secondary and mental health care providers. She was appointed Dame Commander for services to public health in 2003 and has held the chair of the Health Education Authority, Health Development Agency, and the NHS Institute for Innovation and Improvement. Dame Yve explained: “The West Midlands has a large, diverse and stable population with many incredible health and education institutions, and both BHP and the new ICS enable integration of these organisations to benefit our citizens. In the wake of COVID-19, we have a valuable opportunity to rethink care pathways and streamline research delivery to ensure innovations reach patients more quickly. It’s a privilege to be part of both teams at such a crucial point in time.”

Ed Smith served as Pro Chancellor at the University of Birmingham for 10 years as well as leading roles with the NHS and holding the chair of a number of healthcare organisations and committees. He is passionate about delivering positive change for patients who rely on the NHS, having overseen the establishment of NHS Improvement and supporting the performance of a number of Trusts. He commented: “Excellence and innovation in the NHS is driven by research – from basic science in University laboratories to clinical trials in our hospitals. Birmingham Health Partners is a powerhouse of research at the heart of an ambitious city and region, with a strong track record of scaling innovation from the bench to the bedside at pace.

“COVID-19 has emphasised the critical importance of collaboration between NHS, academia and industry and, in these unprecedented times, the strength of the existing BHP alliance enabled us to adapt, collaborate and tackle the pandemic head-on. It is an incredibly challenging yet exciting time to join the partnership and direct its research strategy.”

BHP is committed to achieving health and economic impact through harnessing the combined strength and expertise of its members.

AI and advanced imaging could diagnose childhood brain tumours without biopsy

Written by Louise Stanley on 19/02/2021. Posted in Cancer outcomes, Early diagnosis and detection.

A study led by Birmingham Health Partners member organisations has found that combining advanced imaging and artificial intelligence techniques can accurately classify the characteristics of common types of childhood brain tumours – paving the way for more rapid non-invasive diagnosis.

Brain tumours in a particular part of the brain, called the posterior fossa, are the largest cause of death from cancer in children. There are three main types of tumour that occur in the posterior fossa, and being able to characterise them quickly and efficiently can be challenging without confirmation via a biopsy, which is invasive.

Now a new study, carried out in collaboration with researchers from WMG at the University of Warwick and published in Scientific Reports, has found tumour diagnostic classification can be improved by using an advanced and non-invasive imaging technique known as ‘diffusion weighted imaging’ in combination with machine learning (AI). This means that the tumour can be characterised and treated more efficiently.

Diffusion weighted imaging involves the use of specific advanced MRI sequences, as well as software that generates images from the resulting data which uses the diffusion of water molecules to generate contrast in MR image. Experts can then extract a ‘map’ which can be analysed to give more information about the tumour.

The study involved 117 patients at five primary treatment centres across the UK, with images taken using machines across 12 hospitals. The images were analysed by both an experienced radiologist and an expert scientist in paediatric neuroimaging. Analysis from the images were fed to AI algorithms to successfully discriminate the three most common types of paediatric posterior fossa brain tumours, non-invasively.

Professor Andrew Peet, NIHR Professor in Clinical Paediatric Oncology at BHP founder-members the University of Birmingham and Birmingham Women’s and Children’s NHS Foundation Trust, said: “When a child comes to hospital with symptoms that could mean they have a brain tumour, that initial scan is such a difficult time for the family and understandably they want answers as soon as possible.

“Here we have combined readily available scans with artificial intelligence to provide high levels of diagnostic accuracy that can start to give some answers.

“Previous studies using these techniques have largely been limited to single expert centres. Showing that they can work across such a large number of hospitals opens the door to many children benefitting from rapid non-invasive diagnosis of their brain tumour.

“These are very exciting times and we are working hard now to start making these artificial intelligence techniques widely available.”

Professor Theo Arvanitis, Director of the Institute of Digital Health at WMG, University of Warwick, and one of the authors of the study, added: “If this advanced imaging technique, combined with AI technology, can be routinely enrolled into hospitals it means that childhood brain tumours can be characterised and classified more efficiently, and in turn means that treatments can be pursued in a quicker manner with favourable outcomes for children suffering from the disease.”

The research was supported by Cancer Research UK, EPSRC Cancer Imaging Programme at the Children’s Cancer and Leukaemia Group, the Medical Research Council, National Institute for Health Research (NIHR), Children’s Research Fund, Poppyfields and Help Harry Help Others.

man pointing towards illsutration of legal scales

Advancing UK Regulatory Science Strategy in the Context of Global Regulation: a Stakeholder Survey

Written by Louise Stanley on 17/02/2021. Posted in Birmingham Health Partners.

New study published in Therapeutic Innovation & Regulatory Science today (17th February 2021) from the Birmingham Health Partners Centre for Regulatory Science and Innovation

Background

The UK’s transition from the European Union creates both an urgent need and key opportunity for the UK and its global collaborators to consider new approaches to the regulation of emerging technologies, underpinned by regulatory science. This survey aimed to identify the most accurate definition of regulatory science, to define strategic areas of the regulation of healthcare innovation which can be informed through regulatory science and to explore the training and infrastructure needed to advance UK and international regulatory science.

Methods

A survey was distributed to UK healthcare professionals, academics, patients, health technology assessment agencies, ethicists and trade associations, as well as international regulators, pharmaceutical companies and small or medium enterprises which have expertise in regulatory science and in developing or applying regulation in healthcare. Subsequently, a descriptive quantitative analyses of survey results and directed thematic analysis of free-text comments were applied.

Results

Priority areas for UK regulatory science identified by 145 participants included the following: flexibility: the capability of regulations to adapt to novel products and target patient outcomes; co-development: collaboration across sectors, e.g. patients, manufacturers, regulators, and educators working together to develop appropriate training for novel product deployment; responsiveness: the preparation of frameworks which enable timely innovation required by emerging events; speed: the rate at which new products can reach the market; reimbursement: developing effective tools to track and evaluate outcomes for “pay for performance” products; and education and professional development.

Conclusions

The UK has a time-critical opportunity to establish its national and international strategy for regulatory science leadership by harnessing broader academic input, developing strategic cross-sector collaborations, incorporating patients’ experiences and perspectives, and investing in a skilled workforce.

Read the full study on the publication website (opens as PDF).

a pill dispenser with various medications

Funding boost to research multimorbidity in hospital patients

Written by Louise Stanley on 11/02/2021. Posted in Health inequalities, Inflammation and chronic disease.

Scientists have been given almost £4m to improve understanding of multimorbidity in hospital patients.

Research led by Newcastle University will focus on multiple long-term conditions in hospitalised patients and is funded by the Medical Research Council (MRC) and National Institute for Health Research (NIHR).

The four-year ADMISSION study aims to transform understanding of how different long-term conditions cluster or group together, why people are affected more often by some groups of conditions than others, and how hospital systems look after them.

NHS pressures

The number of people who have more than one long-term health condition, known as multimorbidity, is growing. This is increasing pressure on healthcare providers, such as the NHS, as these patients have complex needs – often staying in hospital for longer and taking more time to recover.

However, hospital systems are designed to treat single health conditions. Patients with multimorbidity often find their care is inefficient and unsatisfactory. For providers, this inefficiency translates into more costly care and potentially worse outcomes.

To find new ways to deliver hospital care, experts want to understand how long-term health conditions develop, and why particular conditions occur in groups.

Despite the recognised importance of multimorbidity in hospital patients, there has been little research in this area to date.

Professor Miles Witham, Deputy Lead for NIHR Newcastle BRC’s Ageing Syndromes theme, is co-investigator of the ADMISSION study.

He said: “We are delighted to have received this substantial award from the MRC and NIHR to fund our research.

“The results of ADMISSION will provide a springboard for developing, testing and delivering novel approaches to transform care for people with multiple long-term conditions before, during and after admission to hospital.”

ADMISSION will use cutting-edge data science, computing and statistical approaches to analyse ‘big data’ from routinely-collected healthcare records, along with information from the UK Biobank and the Scottish Health Research Register (SHARE).

Its focus will be on clusters of conditions: to describe how they occur across the population, to understand the mechanisms that explain them, and to examine their impact on patient pathways through healthcare.

Future care

This knowledge will inform the design of future care and treatments, with potential both to reduce costs, and to improve health outcomes for the millions of patients with multimorbidity admitted to hospital each year.

Newcastle University is leading the study, collaborating with Newcastle Hospitals NHS Foundation Trust, University of Birmingham, Manchester Metropolitan University, University College London and the University of Dundee.

Professor Liz Sapey, Professor of Acute and Respiratory Medicine at BHP founder-member the University of Birmingham, said: “As a doctor working in acute medicine, I see many people admitted with multiple long-term conditions.

“Currently, we do not understand how and why some illnesses cluster together, and so do not know the best ways to care for these patients.

“Our expertise in using ‘big data’ from patient records through our PIONEER Health Data Hub here in Birmingham forms an important part of the ADMISSION programme.

“Describing how these illnesses cluster together, as part of the ADMISSION collaborative, is a crucial first step to improving care for patients with multiple long-term conditions.”

For more information, visit: www.admissioncollab.org

Doctor Showing Patient Test Results On Digital Tablet stock photo

New med-tech partnership to assess quality of life in clinical trials and care

Written by Louise Stanley on 02/02/2021. Posted in Clinical trials, Health inequalities.

BHP founder-member the University of Birmingham has today announced a partnership with med-tech company Aparito to co-develop digital platforms to assess patient quality of life and symptoms in clinical trials and routine NHS care.

The partnership will see the configuration of Aparito’s flagship software platform Atom5™, and brings together international experts in patient-reported outcomes (PROs) methodology and input from patients and clinicians, with cutting-edge and innovative technology.

The aim of the partnership is to co-develop multiple digital PROs for use in a wide range of disease groups to assess treatment safety and effectiveness from the patient perspective and enhance the patient experience of clinical trials and routine care. These data will support patient care and provide evidence to inform regulators and policy makers such as the Medicines and Healthcare products Regulatory Agency (MHRA), and the National Institute for Health and Care Excellence (NICE).

Professor Melanie Calvert, National Institute for Health Research (NIHR) Senior Investigator and Professor of Outcomes Methodology at the University of Birmingham’s Centre for Patient-Reported Outcomes Research (CPROR), said: “It is essential that we capture information on the impact of disease and treatment on patient symptoms and quality of life.

“This information can help regulators decide if a treatment is safe and effective and answer important questions from patients such as ‘how will it make me feel?’

“We are delighted to be partnering with Aparito to use cutting edge methodology and technology to advance this area and benefit patients.”

Dr Elin Haf Davies, CEO of Aparito, which is based in Wrexham in the UK and Leiden in the Netherlands, said: “We are highly honoured to enter into this partnership with the CPROR at the University of Birmingham.

“Professor Melanie Calvert and her team are highly regarded and international leaders in PRO methodology. We very much look forward to expanding on this work to provide a digitalised and personalised solution, in 2021 and beyond.”

One of the projects is the new National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre (NIHR SRMRC) ‘PRiORiTy’ (Patient Reported Outcomes Research in Trauma) study.

In this study, the team of experts at BHP founder-members the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust will assess patient symptoms following traumatic brain injury to help tailor care to patient needs.

This is an important issue for patients, as explained b ypatient advocates involved in the design of the study, Luke and Jackie Flavell: “We feel it is really important for patients to report symptoms of traumatic brain injury as early as possible and doing this electronically would save valuable time and improve patient care. We are very much looking forward to working with CPROR on the PRiORiTy study.”

Daniel Lewi, Head of Business Development at Aparito, added: “Working with the team at University of Birmingham to provide a technology solution for PRiORiTy has highlighted how deeply clinicians care about the patient experience and how they can improve treatment within the patient cohort.

“Having such an approachable and knowledgeable team has allowed the University of Birmingham to detail very specifically how we can adapt our Aparito Atom5™ technology to really change a patient’s life and we cannot wait to work with the team again on future projects.”